Association of genes of protease-antiprotease balance pathway to lung function and emphysema subtypes

BMC Pulmonary Medicine

Table 5 Distribution of MMP9/TGFB1 combined genotypes according to the existence and severity of centrilobular changes

Genotype combination (MMP9rs3918242-TGFB1rs2241718)	No radiologic changes^*	Radiologic changes	OR (95% CI)^†	Subnormal^‡ changes	OR (95% CI)^†	Pathological^§ changes	OR (95% CI)^†
Genotype combination (MMP9rs3918242-TGFB1rs2241718)	n (%)	n (%)		n (%)		n (%)^*
Wild type-wild type ^#	375 (52.8)	130 (58.3)	1.0	52 (50.0)	1.0	78 (65.5)	1.0
Heterozygote/ homozygote ⁺	281 (39.6)	81 (36.3)	0.83 (0.60-1.15)	43 (41.3)	1.07 (0.69-1.68)	38 (31.9)	0.66 (0.43-1.02)
Heterozygotes or homozygotes ^±	54 (7.6)	12 (5.4)	0.63 (0.36-1.09)	9 (8.7)	1.29 (0.68-2.46)	3 (2.5)	0.22 (0.08-0.61)

^*Reference category.
^†Adjusted for age, sex, pack-years and years of asbestos exposure.
^‡The changes were considered as subnormal if the emphysema subtype score was < 1 (< 2 in emphysema sum score).
^§The changes were considered as pathological if the emphysema subtype score was ≥ 1 (≥ 2 in emphysema sum score).
^# MMP9 CC/TGFB1 GG.
⁺ MMP9 CT/TGFB1 GG or MMP9 CC/TGFB1 GA.
^± MMP9 CT/TGFB1 GA or MMP9 TT or TGFB1 AA.

ISSN: 1471-2466